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Natural killer (NK) cells are innate lymphoid cells that hold tremendous potential for
effective immunotherapy for a broad range of cancers. Due to the mode of NK cell killing,
requiring one-to-one target engagement and site-directed release of cytolytic granules,
the therapeutic potential of NK cells has been most extensively explored in hematological
malignancies. However, their ability to precisely kill antibody coated cells, cancer stem
cells, and genotoxically altered cells, while maintaining tolerance to healthy cells makes
them appealing therapeutic effectors for all cancer forms, including metastases. Due
to their release of pro-inflammatory cytokines, NK cells may potently reverse the anti-
inflammatory tumor microenvironment (TME) and augment adaptive immune responses
by promoting differentiation, activation, and/or recruitment of accessory immune cells to
sites of malignancy. Nevertheless, integrated and coordinated mechanisms of subversion
of NK cell activity against the tumor and its microenvironment exist. Although our
understanding of the receptor ligand interactions that regulate NK cell functionality
has evolved remarkably, the diversity of ligands and receptors is complex, as is their
mechanistic foundations in regulating NK cell function. In this article, we review the
literature and highlight how the TME manipulates the NK cell phenotypes, genotypes,
and tropism to evade tumor recognition and elimination. We discuss counter strategies
that may be adopted to augment the efficacy of NK cell anti-tumor surveillance, the
clinical trials that have been undertaken so far in solid malignancies, critically weighing
the challenges and opportunities with this approach.
Keywords: NK-cell subsets, KIR-HLA interactions, tumor microenvironment, cancer stem cells, clinical application
Introduction
Cancer is a generic groupof over 100 diseases unified by fundamental characteristics acquired during
their clonal evolution (1), including tumor-promoting inflammation and escape from immune
surveillance (2, 3). Increased cancer incidence is associated with immunodeficiency (4, 5) and
sustained immunosuppression (6–8). This supports the immunological surveillance hypothesis that
postulates that as well as conferring protection from infectious pathogens, the immune system also
guards against cancer (9). A prospective study of a large cohort of Japanese inhabitants followed
up for 11 years uncovered an association of low natural cytotoxicity of peripheral blood natural
killer (NK) cells with approximately 40% increased cancer risk compared to individuals with high
cytotoxicity activity (10). This is reinforced by findings of decreasedNK-cell activity among relatives
of patients diagnosedwith familialmelanoma (11), implicatingNK cells in tumor surveillance.Novel
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immunotherapies have recently demonstrated unprecedented
success in selected cancer types (12, 13). Heightened interest in
applicability of NK cells for cancer immunotherapy has been
evoked by improved methodologies for their purification, molec-
ular and phenotypic characterization. This progress is a result of
a deeper understanding emerging from 40 years of scrutiny of
their roles in anti-cancer immunity. In this article, we discuss the
current knowledge on howNK cells recognize and kill cancer cells
while sparing the normal healthy cells, how the cancer and its
associated cells exploit this biology. We discuss the strategies that
may be employed to derive effective medicine, the promise and
challenges of these approaches for solid malignancies.
NK Phenotypes and Natural Cytotoxicity
Against Solid Tumors
Natural killer cells comprise 10–15% of peripheral blood lympho-
cytes and classically display a half-life of approximately 7–10 days
in circulation (14–16). However, some subpopulations generated
by cytokine stimulation or viral infections may display prolonged
persistence (17–19). NK cells arise from lineage restricted pro-
genitor cells derived fromCD34+ common lymphoid progenitors
through a process regulated by basic leucine zipper transcription
factors, E4-promoter binding protein 4 (E4pb4), Ets1 (20, 21),
and the T-box transcription factors, T-bet, Eomes, as well as ID2
(inhibitor of DNA binding). In their absence, fewer numbers of
NK cells develop (22–25) and exhibit functional alterations (26).
Terminally differentiated NK cells lack phenotypic markers of B
and T lymphocytes and are distinguished further by their greater
size and cytoplasmic granularity. They express CD56 neural cell
adhesion molecule and are thus phenotypically categorized as
CD3-CD19-CD56+ innate lymphoid cells (27–29).
Functionally, NK cells can lyse directly virus-infected or trans-
formed cells without prior sensitization (28, 30), mediated by
natural cytotoxicity receptors (NCRs) NKp30 (CD337), NKp44
(CD336), and NKp46 (CD335) that belong to the Immunoglob-
ulin superfamily (31). NKp30 is constitutively expressed and
recognizes B7-H6 tumor antigens (expressed on leukemia, lym-
phomas, carcinomas, and melanomas) (32). NKp44 is expressed
only on activated human NK cells and binds viral hemagglutinin
(HA) and HA-neuraminidase (HN) as well as tumor-associated
ligands (33). NKp46 is expressed on both resting and activated
NK cells in mice and men and can inhibit growth of tumor
metastases in mice (34, 35), although its ligands have yet to
be identified. The NK group 2D (NKG2D, CD314) is a lectin-
like type 2 transmembrane homodimeric receptor that is con-
stitutively expressed on all NK cells (36). It transduces activat-
ing signals upon binding to its ligands major histocompatibil-
ity complex (MHC) class 1-related chains A and B (MICA and
MICB) and viral UL16 binding proteins (ULBPs). These stress
induced-ligands are expressed on tumor, but not healthy cells,
as a result of heat shock, viral infection, or genotoxic stress by
DNA damage (37). NKG2D ligation induces phosphorylation of
YINM motifs on DAP10, allowing recruitment and activation
of the p85 subunit of phosphatidylinositol-3-kinase (PI3K) and
growth factor receptor-bound protein 2 (GRB2) to trigger NK
cytotoxicity (38). We recently demonstrated that NKG2D was
highly expressed by glioblastoma (GBM) infiltrating NK cells
in situ (39). Antibody blockade of NKG2D rescued approximately
50% stress ligand-bearing GBM but not K562 chronic myeloge-
nous leukemia (AML) cells, from lysis by donor NK cells in vitro
(40). This emphasizes the importance of activation signaling via
NKG2D for NK cell cytotoxicity. Indeed, proteolytic cleavage of
NKG2D ligands by ADAM 10 and 17 proteases (a disintegrin
and metalloproteinase) sheds soluble ligands into serum to cir-
cumvent cytotoxicity via NKG2D receptor (41, 42), and is a com-
mon aberration in cancer (43). Soluble MICA/B and ULBPs have
been detected in sera of patients with diverse solid malignancies
(44), where soluble ULBP2 distinguished early stage pancreatic
adenocarcinoma from healthy subjects. Elevated ULBP2 could
identify melanoma patients at risk for disease progression and
was prognostic in patients with early stage B-cell chronic lym-
phocytic leukemia (45–47). Conversely, others demonstrated that
hypoxia induced microRNAs miR-20a, miR-93, and miR-106b
downregulated NKG2D ligands on GBM cells as a mechanism
of immunological escape (48). Genome wide association stud-
ies also identified a MICA-A5.1 allelic variant with a frameshift
mutation that results in a truncated protein that is released as
a membrane-anchored molecule in exosomes in human papil-
loma virus induced cervical cancer in a Swedish cohort (49,
50). Another MICA variant, rs23596542, was identified in hep-
atitis C virus induced hepatocellular carcinomas (HCC) from
a Japanese population (51). Both cleaved MICA and exosomal
MICA-A5.1 result in high serum levels of solubleMICA that inter-
acts with NKG2D and prevents its interaction with membrane
bound ligands. Recently, the GBM derived metabolite, lactate
dehydrogenase isoform 5 (LDH5), was demonstrated to upregu-
late the NKG2D ligands MICA/B and ULBPs on monocytes from
healthy individuals in vitro and on circulating macrophages from
patient derived breast, prostate, and HCC as a further means to
subvert NK cell surveillance (52). This would lead to NKG2D
receptor downregulation through internalization, degradation,
and/or desensitization (53). Ultimately, diminished NK cytotox-
icity ensues due to chronic exposure to ligand expressing cells,
consistent with the discontinuity theory of immunity (54). A
caveat to interpreting causality of soluble ligands in patient sera
to attenuated NKG2D receptor levels is the presence of trans-
forming growth factor β (TGFβ) that also diminishes NKG2D,
as reported in GBM (55). Another emerging concept coined split
anergy proposes that NK cell-monocyte/macrophage cross-talk
in vitro results in anergic NK cells that are not cytotoxic but
secrete cytokines that enhance differentiation of cancer stem cells
(CSCs) (56). CSCs are minor subpopulations within the tumor
capable of self-renewal by asymmetrical cell division to main-
tain the tumor’s cellular heterogeneity (57). CSCs are resistant
to conventional anti-cancer therapy (57, 58) and are proposed
to drive malignant progression. Differentiated cells are thought
to be more resistant to NK lysis (59, 60), but more responsive
to the standard treatment. Thus, NK-cell/macrophage crosstalk
may halt malignant progression by directly killing and/or dif-
ferentiating the CSCs (56). Although largely observed in vitro,
split anergy may have clinical implications for the impact of NK-
cell/macrophage crosstalk in tumor surveillance in vivo. Never-
theless, natural cytotoxicity is a tumor-dependent killing mecha-
nism that varies in potency because although NCRs and NKG2D
are constitutively expressed on NK cells in most individuals,
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different tumors variably express tumor-associated antigens and
NKG2D ligands.
NK Subsets
On the basis of the density of CD56, NK cells can be further
subclassified as CD56bright subsets (61) that also express high
levels of -selectin (CD62L), an adhesion molecule that mediates
interaction with the vascular endothelium (62). CD56bright NK
cells account for only 10% of circulating peripheral blood NK
cells but represent a dominant phenotype in secondary lymphoid
tissues. They constitutively express high affinity heterotrimeric
interleukin (IL)-2Rαβγ receptors, maintain long telomeres, and
proliferate in response to low concentrations of IL-2 (63, 64).
Unlike T cells, NK cells do not secrete IL-2 (65) but CD56bright
subsets are denoted by secretion of other cytokines, including
interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α),
IL-5, IL-10, and IL-13. Notably, IFN-γ promotes T-helper type
1- (Th1) responses that enhance effector functions of both NK
cells and cytotoxic T lymphocytes (CTLs) (66, 67), up-regulate
class I and class II MHC (68) on antigen presenting cells, as
well as costimulatory molecules on macrophages (67). CD56bright
subsets express CC-chemokine receptors 7 (CCR7), CCR5, and
CXCR3 (69) that allow their preferential recruitment to tumor
and inflamed tissues (70, 71). CD56bright NK cells also secrete
granulocyte colony-stimulating factor (G-CSF) and granulocyte
macrophage colony-stimulating factor (GM-CSF) (67, 72, 73)
that promote homing to secondary lymphoid organs through
endothelial venules (74).
In contrast, the majority (approximately 90%) of NK cells
in steady state peripheral blood are CD56dim, and are consid-
ered to differentiate from the CD56bright CD94/NKG2A+ sub-
sets through transitional loss of CD94/NKG2A and CD62L.
Acquisition of CD57 and killer immunoglobulin like recep-
tors (KIRs) denotes their terminal differentiation to CD56dim
CD57+CD62L-CD94/NKG2A- KIR+ mature NK cells. The
CD56dim subsets are more cytotoxic against target cells compared
to the CD56bright subsets and proliferate in response to IL-2 and
IL-15 stimulation through signaling via their heterodimeric IL-
2Rβγ/IL-15Rα. CD56dim CD57+ subsets exhibit replicative senes-
cence as indicated by shortened telomeres and diminished pro-
liferation in response to stimulation with cytokine combinations
ex vivo (75, 76). CD56dim subsets secrete low IFN-γ, even after
activationwith IL-2, or combination IL-15/IL-21. They lackCCR7
but do express CXCR1, CXCR2, and low density CXCR3, as well
as CX3C chemokine receptors 1 (CX3CR1high). This traditional
designation of CD56dim as “potent killers” and CD56bright subsets
as “cytokine producers” might be oversimplified, as both sub-
sets can perform either function when appropriately stimulated
(77). NK cells dynamically adjust their phenotypes in response
to the changing cytokine concentrations, ligand density, and cell
types present in their microenvironment. Thus, it is debated
whether the phenotypic subsets represent distinct maturation
stages that are also functionally independent subpopulations,
regardless of age, diurnal fluctuations, and microenvironments
in diseases states, such as cancer (78). If subset characteris-
tics change dynamically depending on their microenvironment,
challenges for selecting a priori suitable subsets for anti-cancer
therapy will be inevitable. All human NK cell subsets express
a range of other adhesion molecules, including CD2, CD44,
VLA-5 α chain (CD49e), lymphocyte function associated anti-
gen (LFA-1), and intracellular adhesion molecule-1 (ICAM-1).
Their density vary and thus impact trafficking patterns to various
tissues and ability to form functional immunological synapses
during immune responses (71). Both CD56bright and CD56dim NK
cell subsets secrete chemokines such as monocyte chemotactic
protein-1 (MCP-1, CCL2),macrophage inflammatory protein 1-α
(MIP1-α, CCL3), macrophage inflammatory protein 1-β (MIP1-
β, CCL4), and regulated on activation normal T cell expressed
and secreted (RANTES, CCL5) (72). These chemokines fur-
ther recruit, activate, and enhance antigen presentation of other
immune cells at sites of inflammation, required for full-fledged
immune responses (79, 80).
Trafficking to the Solid Tumor
Microenvironment
The microenvironment of solid tumors poses a formidable chal-
lenge to NK cell efficacy due to chronic immune suppressive
signals that select for tumor cells with altered immunogenicity,
while simultaneously hindering both infiltration and activation
of NK cells at tumor nests (81). The tumor secretes TGFβ (82,
83) vascular endothelial growth factor (VEGF), prostaglandin E2
(PGE2), and IL-10 that suppress T cell proliferation and cyto-
toxic responses (84) (Figure 1). These factors also downregulate
class I MHC, skew dendritic cells toward an immature, tolero-
genic, immature phenotype (85). TGFβ and PGE2 generate a
highly heterogeneous population of myeloid derived suppressor
cells (MDSCs) that comprise granulocytes, macrophages, and
dendritic cells arrested at various differentiation stages (86). In
response to hypoxia in the tumor microenvironment (TME),
MDSCs upregulate arginase activity and inducible nitric oxide
synthase (iNOS) (Figure 1) that inhibit T cells through NO
signaling (87). This further depletes intracellular -arginine and
enhances production of reactive oxygen species (ROS) that dimin-
ish immune surveillance through shedding of NKG2D ligands
(87). In addition, MDSCs secrete IL-10 and through membrane
bound TGFβ, polarize tumor associated macrophages (TAMs)
toward anM2- like anti-inflammatory phenotype (86) (Figure 1).
A seminal study demonstrated that a subpopulation ofmouse GR-
1+CD11b+F4/80+ mononuclear MDSCs expressing the NKG2D
ligand RAE-1 did not suppress, but in fact activated NK cells
to produce IFN-γ and abolished tumor growth (88). Depletion
of this population fueled tumor growth confirming their pro-
tective role against cancer. Although this study defines func-
tional plasticity within the highly heterogeneous MDSC pool,
the study was performed in a NK cell sensitive, relatively homo-
geneous mouse tumor. The findings may not easily translate
to biochemically complex microenvironments of heterogeneous
solid tumors in humans. The function of the RAE-1 expressing
GR-1+CD11b+F4/80+ does not easily reconcile findings of the
NK tolerizing role of NKG2D ligands on TAMs (39, 52). Others
reported that coculture with Gr-1+CD11b+ MDSCs inhibited
cytotoxicity of IL-2 activated NK cells against Yac-1 cells and
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FIGURE 1 | Immune suppressive mechanisms of the solid tumor
microenvironment. Tumor-derived immunosuppressive mechanisms include
secreted cytokines and chemokines that recruit and sustain immature and
suppressive immune cells. These in turn secrete Th2 factors that propagate
the cycle to create a chronic anti-inflammatory environment that promotes and
predominates malignant progression (left). NK cell therapy has the potential to
reverse the anti-inflammation to engender dominant pro-inflammatory signaling
through secretion of IFN-γ, Th1 cytokines, and activation of both innate and
adaptive immune cells (right). By elimination of tumor cells and immature
suppressive cells (e.g., iDCs, MDSCs, cancer stem cells), NK cells have the
potential to reverse the anti-inflammatory signals and eliminate tumor
progression. iDCs, immature dendritic cells; mDCs, mature dendritic cells;
MDSCs, myeloid derived suppressor cells; PGE2, prostaglandin E-2; IDO,
indoleamine-2,3-dioxygenase; VEGF, vascular endothelial growth factor;
TGFβ, transforming growth factor-beta; TNF-α, tumor necrosis factor-alpha;
IFN-γ, interferon-gamma; IL, interleukin; iNOS, inducible nitric oxide synthase;
ROS, reactive oxygen species; CTLs, cytotoxic T lymphocytes (CTLs); Tregs,
regulatory T lymphocytes; CSC, cancer stem cells.
that this was mediated via membrane bound TGFβ and signaling
via signal transducer and activator of transcription-5 (STAT5)
(89). Thus, polyclonal MDSCs may exhibit functional plasticity
to induce anti-tumor or pro-tumor effects depending on their
subset phenotype, tumor type, or microenvironment encountered
(Figure 1).
Although CSCs represent a minor population in the TME, they
too contribute to immune suppression (90, 91) through STAT3
(92), a signaling hub utilized by diverse cytokines and tumor
infiltrating immune cells to markedly suppress their functionality
(93). The transcriptional activity of nuclear factor-kappa beta
(NFκB) also regulates the function of CSCs and immune effec-
tors at the tumor site (94). Differentiated oral epithelial tumors
exhibit higher NFκB activity and are resistant to NK-mediated
cytotoxicity compared to their CSC counterparts (59). Inhibition
of NFκB in differentiated carcinoma cells, or in non-transformed
keratinocytes, increased sensitivity to NK cell lysis (95), impli-
cating NFκB survival signaling in resistance to NK lysis. Indeed,
CSCs from oral squamous carcinomas and colorectal cancers with
diminished NFκB levels are more sensitive to NK lysis compared
to their differentiated counterparts (59, 60, 96). In contrast, NK
cells preferentially lyse GBMCSCs despite constitutively activated
STAT3 and NFκB signaling (97, 98). Instead, it was reported that
low class I MHC and high PVR and Nectin-2 expression levels
underlie their sensitivity to NK cells (97, 98). This discrepancy
may reflect diversity in oncogenic signaling pathways of CSCs
from different tissues.
The tumor secretes chemokines CXCL8, CCL2, IL-1,
and TNF-α that recruits macrophages and suppressive
CD4+CD25+CD127lowFOXP3+ Tregs to the tumor site
(Figure 1). Tregs have been demonstrated to inhibit NK cells
from gastrointestinal stromal tumors (GIST) by competing for
IL-2 availability and secrete IL-4, indoleamine-2,3-dioxygenase
(IDO). Tregs express membrane bound TGFβ that inhibits
NKG2D and NKp30 by cleaving their ligands off malignant
cells (99, 100). Tumor-derived IDO promotes production of the
immunosuppressive tryptophan catabolite -kynurenine that
interferes with IL-2 induced expression of NKp46 and NKG2D
receptors that are required for target cell recognition and killing
(101). In contrast to CD4+CD25+CD127lowFOXP3+ Tregs, we
recently identified CD8+CD28–Foxp3+ Tregs that were induced
in the GBM microenvironment (39). These Tregs might tolerize
tumor infiltrating antigen presenting cells through IL-10 induced
immunoglobulin-like transcripts (ILT)-2, ILT3, ILT4, and
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decreased expression of CD40, CD80, and CD86 costimulatory
molecules (39). Decreased Tregs have been associated with
improved NK cell activity in GIST, melanoma, and GBM after
treatment with Imatinib, and DC exosomes (102) or vaccination
(103), underscoring the clinical impact of these suppressive cells.
Melanoma and colorectal tumor associated fibroblasts could
inhibit NK cell activity through cell–cell contact in vitro (104,
105) and through secretion of PGE2 or IDO that abrogated IL-2
induced NKp44, DNAM-1, and NKp30 upregulation (106). Thus,
targeting IDO in cervical cancer increased NK cell accumulation
at the tumor site and inhibited growth (101).
Indeed, increased infiltration of NK cells into tumor lesions
of diverse histological types, such as GBM (107), solid metas-
tases (108) lung, gastric, colorectal, as well as head and neck
cancers, have been associated with good prognosis (70, 109–112).
In gastric cancer, increased NK cell infiltration correlated with
reduced invasion, reduced lymph nodesmetastases, and improved
outcome. A caveat to these early studies, however, was the uti-
lization of single staining immunohistochemistry against CD56
or CD57 markers that are also expressed by CD8+ T cells (107)
and some tumor types (113). Moreover, CD57 is only expressed
on a subset of CD56dim mature NK cells (75, 76). Thus, the degree
of NK cell infiltration in tumors is difficult to ascertain from
these studies, as both overestimation and under representation
of the figures is possible. Staining for NKp46 that is expressed
by all NK cells revealed that renal cell carcinomas (RCC) and
GIST had substantial NK cell infiltration (114, 115). However,
NK cells infiltrating the RCC were not cytotoxic and upregulated
CD94/NKG2A inhibitory receptor. NK cells infiltrating the GIST
tumors ostensibly expressed the immunosuppressive NKp30c iso-
form whose surface levels were also prognostic in these patients
(114, 115). Other studies reported scarce infiltration of HCC
and RCC by NK cells. The NK cells were functionally anergic as
indicated by diminished NKp30, DNAM-1 expression, reduced
degranulation or stayed in the stroma, and did not contact the
tumor cells (104). Extracellular matrix and tumor cell derived
gangliosides (sialic acid glycoproteins), GM2, andGM3 have been
demonstrated to diminish NK cell cytotoxicity through contact
inhibition to targets, and abrogation of IL-2 dependent prolifera-
tion (116). Furthermore, pre-incubation ofNK cells withGD3 and
GM3, or serum from cancer patients containing shed GD3 prior
to addition of target cells, strongly inhibited NK cell lysis in a dose
dependent manner (117, 118). Again, the effects of serum could
be explained through other mechanisms, such as TGFβ. GD3
and various gangliosides are abundantly secreted into the TME
of patient GBMs in situ (119, 120), potentially providing similar
immunosuppressive mechanisms of escape from NK cell lysis.
Precise mechanisms regulating NK cell recruitment to tissues are
poorly delineated butmay depend on both tumor histological type
and chemokine profiles. Therefore, several experimental therapies
have attempted to augment endogenous NK cell trafficking and
activity at tumor nests. CD27high NK cells in mice are orthologs
of human CD56bright cells, and in both species, these NK sub-
sets express CXCR3 and are attracted to CXCL9 and CXCL10
chemokines at tumor sites (121, 122). CD56dim NK cells, however,
express CX3CR1 and have been detected in breast, lung, and
colorectal cancer biopsies. In the latter, the NK cells remained in
the stroma and were not in direct contact with the malignant cells
despite elevated levels of chemokines typically expressed by both
CD56dim and CD56bright subpopulations (123). This might indi-
cate insufficiency of chemokines alone in determining the impact
of tumor infiltrating NK cells. Remarkably, the chemoattractant
chemerin has been shown to favor infiltration of melanoma by
NK cells, reducedMDSCs, and immunosuppressive plasmocytoid
DCs (81, 124). Whole genome expression datasets confirmed
that chimerin was prognostic of improved outcome in melanoma
patients and expression is lost during malignant progression of
several solid tumors. In B16 transplantable mouse melanoma,
chimerin overexpression or exogenous injection in the context of
its chemokine-like receptor 1 diminished tumor growth (124). It is
not known whether CD56dim and CD56bright subsets are differen-
tially recruited to the tumor because of their different chemokine
receptor profiles. It is possible that CD56bright subsets might be
increased in the TME as a consequence of their enhanced prolifer-
ative capacity and or propensity for surviving oxidative stress con-
ditions (125) that typify the TME. Both CD56dim and CD56bright
subsets may express CD16, a low affinity receptor (FcγRIII) that
binds the constant Fc chain of antibody (126), inducing NK cell
activation and killing of antibody coated cells through antibody-
dependent cellular cytotoxicity (ADCC). Human breast cancer
infiltrating CD56bright NK cells expressing low levels of CD16
but heightened expression of activation markers NKp44, CD25,
CD69, and NKG2D were reported (127). Similarly, we reported
that CD56dim CD16- NK cells that infiltrate patient GBM lesions
expressed NKG2D (39). Loss of CD16 on tumor infiltrating NK
cells is one mechanism proposed for induction of split anergy (60,
128). Tumor infiltrating NK cells purified by negative selection
from ascites fluid from ovarian cancer patients produced less IFN-
γ and IL-4, but more IL-10 compared to corresponding periph-
eral blood NK cells (129). Although the CD56dim CD16- subsets
might indicate potential cytotoxicity, their diminished prolifera-
tive potential may result in low intra-tumor effector-target ratios,
thus reducing their killing efficiency. Attenuated cytokine pro-
duction and inability to execute ADCC of antibody-coated cells
due to lack of CD16 might render their cytotoxicity unsustain-
able in hostile solid TMEs. Collectively, these studies indicate a
consistent characteristic in solid cancers of loss of NK cell-tumor
engagement, cleavage of stress ligands, loss of NKG2D receptor
and or CD16, thus diminishing tumor recognition, cytotoxicity,
and ability to execute ADCC of antibody-coated targets.
Antibody-Dependent Cellular Cytotoxicity
Indeed, the induction of ADCC may represent the underlying
mechanism for the unprecedented success of monoclonal anti-
bodies to enhance tumor cell recognition by the immune system,
exemplified by Rituximab against CD20 in lymphoma (130) and
Ipilumimab targeting cytotoxic T-lymphocyte antigen-4 (CTLA-
4) in metastatic melanoma (12). IgG1 is the most frequently used
isotype for humanized antibodies due to serum stability and high
affinity for CD16 onNK cells, or CD32 on neutrophils andmono-
cytes/macrophages (FcγRII). The homozygous FcγRIII-158Val
and FcγRII-131His allelic polymorphisms result in proteins with
higher affinity for IgG1, IgG3, and IgG4. Patients with these
polymorphisms demonstrated greater NK cell–mediated ADCC
(131–133). ADCC is executed by the lytic granules, perforin, and
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granzymes A/B, whereas the release of cytokines and chemokines
leads to inhibition of cell proliferation and angiogenesis (134,
135). Thus, as well as exerting efficacy through immune check-
point inhibition, ipilumimab also triggers ADCC and TNF-α
mediated killing by NK cells (134). Nivolumimab, an IgG4 anti-
body against another immune checkpoint molecule, programed
death-1 (PD-1), has been combined with Ipilumimab to harness
synergism in blocking immune checkpoints and evoke therapeu-
tic benefits greater than either treatment alone (13). Since tumor
cells secrete IL-18 that upregulates PD-1 on NK cells, anti-IL-
18 neutralizing mAb in combination with Nivolumimab may
circumvent tolerization of NK cells. Strong evidence for the anti-
cancer efficacy of ADCCwas obtained with Rituximab in patients
with various lymphoid malignancies of B-cell origin, includ-
ing follicular and aggressive large B-cell non-Hodgkin’s lym-
phoma (130). Trastuzumab/Herceptin for treatment of patients
with metastatic breast (136) and early stage gastric carcinomas
(137), humanized anti-GD2 mAb in melanoma, neuroblastoma,
osteosarcoma, and soft tissue sarcoma patients (138–141) induce
potent ADCC. As well as allelic polymorphisms in FcγRIII, high
antigen expression is required for improved efficacy. A human-
ized CD16-CD33 BiKE (bispecific killer engager) antibody was
demonstrated to strongly activate NK cells against CD33+ AML
blasts when combinedwith pre-treatment with anADAM17 small
molecule inhibitor that prevented shedding of CD16 in vitro
(142). Cetuximab, a chimeric human/mouse antibody targeting
epidermal growth factor receptors (EGFR) for treatment of GBM,
advanced non-small cell lung cancer (NSCLC), ovarian cancer,
and colorectal cancer, induced NK cell mediated ADCC, and
extended overall survival by 3months in head and neck cancer
patients (97, 143, 144). EGFR variant III (EGFRvIII) is a tumor
specific mutant epitope that is expressed on one-third of GBMs
and mediates an aggressive phenotype. Unarmed mAbs against
the EGFRvIII showed promise in GBM preclinical studies, but
limited efficacy in patients (145). The latter was likely the result
of limited penetration of the tumor bed, regrowth of heteroge-
neous tumor due to antigen loss variants, and or resistance due
to redundancy in oncogenic signaling pathways (146, 147). A
promising GBM associated antigen is the cell surface chondroitin
sulfate proteoglycan NG2/CSPG4 that is also expressed on var-
ious cancer forms, including melanomas, leukemia, breast, and
sarcomas, but not in normal differentiated cells in the corre-
sponding tissues (73, 148–150). Elevated NG2/CSPG4 enhances
tumorigenicity, angiogenesis and migration, as well as conferring
resistance to chemotherapy and radiotherapy via distinct mech-
anisms (119, 151–157). We demonstrated that NG2/CSPG4 is
highly expressed by approximately 20–30% of treatment resistant
cells and angiogenic vessels in the TME of 50% of all patient
GBMs (119, 151–156). Elevated NG2/CSPG4 expression was an
independent prognostic biomarker for poor survival. We showed
that combination treatment of adoptively transferred NK cells
with mAb9.2.27 against NG2/CSPG4 in preclinical models of
GBM induced synergistic therapeutic effects through TNF-α, a
IFN-γ release, diminished IL-10, IL-6, and IL-1α. Combination
NK cells+mAb9.2.27 induced potent ADCC mediated by Fcγ-
IIR on microglia/macrophages that resulted in prolonged sur-
vival (158, 159). mAb9.2.27 could not induce ADCC by NK cells
proper, likely because of its IgG2a isotype, known to engageweakly
the Fcγ-RIII on NK cells. However, improved chimeric antigen
receptor conjugated or humanized bispecific antibody constructs
against this antigen have recently been tested in pre-clinical stud-
ies with promising results (160, 161). Natural cytotoxicity and
ADCC are not the only mechanisms NK cells use to eliminate
malignant cells.
NK-Tumor Cells’ KIR-HLA Interactions:
“Missing Self”, “Induced Self” and
Tolerance
Natural killer cells express activating and inhibitory killer
immunoglobulin-like receptor (KIR) genes encoded on chromo-
some 19q13.4 that are inherited and segregate separately from
their ligands. These class 1 human leukocyte antigen (HLA)-A,
-B, and -C are allelic variants that are encoded on chromosome
6p21.3. Mutations in the β2-microglobulin gene and loss of het-
erozygosity on chromosome 6 that harbors the class I and II HLA
are common aberrations in cancer (162, 163). They invariably
lead to downregulated expression of HLA molecules. Although
the current review focuses on NK cells, in heterogeneous tissues
KIRs are also expressed on CD8+ T cell subsets, albeit as a unique
repertoire of single dominant KIR that impacts their function
(164, 165). Through ligation of their KIRs to cognate HLA ligands
on autologous cells, NK cells become educated to distinguish
healthy self-cells (Figure 2A) from non-self cells that lack or
possess poorly recognized polymorphic HLA ligands [deemed
“missing self ” (166); Figure 2B]. These malignant cells exhibiting
HLA loss are thus recognized asmissing self by educated NK cells,
triggering their cytotoxicity (166, 167) (Figure 2B).
Educated NK cells can also distinguish healthy self-cells from
altered-self cells that may express appropriate HLA ligands
but concomitantly express stress-induced ligands (Figure 2C).
Inhibitory KIRs are essential for this exquisite distinction of self
from non-self cells and their main HLA ligand specificities are
HLA-C. We recently demonstrated that although GBMs express
high levels of class I HLA (39, 40), these malignant brain tumors
may nevertheless become targets for NK cells due to the “altered
self ” mechanism (67, 72, 168) (Figure 2C). This is because the
tumor cells concomitantly overexpress stress-induced ligands that
are recognized by activating NKG2D receptors (39, 40, 169).
Although GBM cells proper express low to negligent non-classical
HLA-E, antigen presenting cells that constitute upto 50% of cells
of the TME highly express HLA-E and may contribute to further
tolerization of tumor infiltrating KIR-NKG2A+ NK cells (39,
40). Ligation of the self-HLA ligands to cognate inhibitory KIR
results in phosphorylation of the ITIMs by Src family protein
tyrosine kinases (PTKs). This creates docking sites for protein
tyrosine phosphatases SHP-1 and SHP-2 (170) that inhibit NK
cell activation by dephosphorylating proteins involved in down-
stream activation signaling. This inhibitory signaling maintains
NK cells tolerant to normal self-cells. Ligation of activating KIRs
transduces activating signals through phosphorylation of DAP12
or Fc"RI-γ adaptor proteins containing immunoreceptor tyrosine-
based activation motif (ITAM) by the Src PTKs (171). Down-
stream NK cell cytotoxicity pathways converge on the PI3K/Akt
and mitogen-activated protein kinase (MAPK) pathways. The
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FIGURE 2 | NK cell activation and target recognition. (A) Tolerance to
self. NK cells express inhibitory and activating receptors on the surface and
when interaction with cognate ligands for both activating and inhibitory
receptors is balanced, NK cells remain tolerant and unable to kill the target cell
e.g., normal unstressed self-cells that express class I HLA ligands for inhibitory
receptors. (B) Missing self. A malignantly transformed cell may downregulate
class I HLA but concomitantly express stress induced ligands that are
recognized by NK cell activating receptors. A dominant activating signal is
transduced that outweighs the inhibitory signals, resulting in NK cell activation
and subsequent lysis of the target cell. (C) Altered self. Some cancer types
express normal levels of class I HLA but concomitantly over-express
stress-induced ligands e.g., GBM. Only when the activation signal transduced
by ligation of stress ligands to cognate activating receptors overcomes the
inhibitory signal, will NK cells become activated to lyse the target cell.
ensuing activating signal may override the inhibitory signals and
ultimately, the overall threshold strength of activating or com-
peting inhibitory signals determines whether the NK cell will be
triggered for cytotoxicity (172, 173), cytokine release, or tolerance
against encountered target cells.
However, only 5% of individuals possess all KIR genes in
their genome and different individuals display highly variable
KIR repertoires with up to 30,000 distinct NK cell subsets in
peripheral blood (174). It is estimated that 10–20% autologous
NK cells express inhibitory KIRs that do not recognize HLA-
A, HLA-Bw4, or HLA-C self-alleles. These NK cells are con-
sidered “uneducated” and remain functionally tolerant against
self-cells (175, 176). This is likely due to constitutively expressed
CD94/NKG2A receptor that ligates non-classical HLA-E alleles to
maintain tolerance, in complementation with KIRs to prevent NK
cell autoreactivity (177, 178). This interpretation may be debated
since uneducated cells should not express CD94/NKG2A since
by definition this receptor provides NK cell education. How-
ever, there might be a qualitative difference in KIR-inhibition
and NKG2A inhibition (179). NKG2A induces stronger cytokine
responses and less degranulation than KIRs do. The NKG2A-
inhibition may be easier to overcome and may be more important
in microenvironments where HLA-expression is low. The ligand
HLA-E ismore commonly expressed by hematopoietic tumors but
is less abundantly expressed by solid tumors, in particular GBM.
Other studies, however, demonstrated that NK cells that lack
KIR for self-HLA, or lack self-HLA to cognate KIRs may instead
be educated through CD94/NKG2A/HLA-E interactions. Func-
tional activity manifests in transplant cases where donor NK cells
express low frequencies of KIR or during the early phases after
haploidentical hematopoietic stem cell transplantation (HSCT)
(180, 181) when the donor NK cells’ KIRs have yet to recon-
stitute to pre-transplant levels. However, this might not be a
general mechanism as it was also demonstrated that tolerance
is maintained after HLA-matched sibling transplantation (182).
Discrepancies between these two clinical studies may be due
to emergence of conditions that influence endogenous cytokine
levels. These include graft versus host disease (GvHD), bacterial
infections or reactivation of human cytomegalovirus (CMV), as
well as use of immunosuppressive drugs. Likewise, tolerance of
uneducated NK cells may be abrogated by exogenously adminis-
tered cytokines (179). These NK cells were subsequently shown
to execute graft versus malignancy effects and improve survival
after HSCT for AML/myelodysplastic syndrome (AML/MDS)
(183). In an elegant study, neuroblastoma patients possessing
one or more inhibitory KIRs missing self-HLA ligands (NS-
KIRs) exhibited superior overall survival and progression free
survival when treated with the anti-GD2 mAb 3F8 compared to
patients possessing all KIRs in the presence of self-HLA (S-KIRs)
following chemotherapy or autologous stem cell transplantation
(141). This effect was attributed to the uneducated NK cells, even
though in vitro experiments demonstrated that both educated
and uneducated NK subpopulations were activated for ADCC by
3F8mAb. The difference between the in vitro and in vivo effects
was attributed to increased IFN-γ release after ADCC that upreg-
ulated expression of self-HLA ligands and subsequently tolerized
the educated NK cells expressing S-KIRs. It is also possible that
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other cellular subsetsmay have contributed to the inhibition signal
of the effector cells in patients but not in vitro, such as γδT cells
that also express CD94/NKG2A (184). In fact the interpretation
can be further refined when considering that NK responses are
not of “all or nothing” binary function. NK cell responses are
functionally fine-tuned by the varying combinations of particular
inhibitory KIRs with distinct affinities to cognate HLA ligands
in different individuals formulated in the “rheostat” model (185,
186). However, the contribution of activating receptors has also
been proposed (187). Furthermore, uneducated NK cells edit and
eliminate immature DCs (iDCs) that express low levels HLA-E
through contact dependent ligation of NKp30 (188), and thus
enhance the adaptive response by potentiation of antigen presen-
tation by mature DCs (Figure 1). Thus, uneducated NK cells play
a significant role in shaping NK cell mediated tumor surveillance
and treatment response.
Clinical Basis of “Missing Self” Mechanism
The missing-self recognition (166, 189) has been exploited to the
greatest extent clinically in the context of HSCT for treatment of
leukemia (189). When HLA-matched related or unrelated donors
possess NK cell subsets that express KIRs with specificity for
particular class I HLA ligands that are missing in the recipient’s
cancer, a receptor-ligand mismatch (190) between the donor’s
inhibitory KIR and recipient’s HLA arises (KIR-HLA mismatch)
(Figure 2B) (in allogeneic, transplant setting). This mechanism
has been shown to induce potent NK cell alloreactivity and to
mediate graft versus malignancy effect but not treatment limit-
ing GvHD in some leukemia types (189, 191). Since NK cells
are the first lymphocyte subset to recover following HSCT, it is
likely that they mediate the early graft versus malignancy effects
(192). However, the benefit of KIR-HLA mismatch in unrelated
donor, allogeneic HSCT has been debated. Several contradict-
ing studies reported increased transplant related mortality (193),
reduced overall survival and progression-free-survival (194) due
to infections, resulting in higher relapse rates. Discrepancies such
as age and disease stage of the patient at the time of allograft,
differences in extent of T cell depletion through, either antithy-
mocyte globuline (ATG) use, myeloablative regimen, or source
and number of CD34+ stem cells, may account for the con-
flicting benefits of KIR-HLA mismatch reported (191, 194). The
KIR-HLA interaction models used to determine NK-mediated
graft-versus-leukemia (GVL) may also generate different results
[i.e., HLA-ligand mismatch (189); KIR mismatch (195); receptor-
ligand mismatch (196) or missing ligand (183)]. Recently KIR
allelic polymorphisms have been reported to impact the effect
of KIR-HLA ligand interactions, for example, the 25 alleles of
KIR2DL1have been shown to display variable inhibitory strengths
and duration of expression at the surface after interaction with
HLA-ligands. Thus, donor grafts containing KIR alleles with
appropriate polymorphism motifs are associated clinically with
fewer relapses, less transplant related mortality, and improved
survival (197) regardless of primary disease, T cell depletion, or
donor type. Increased GVL can be demonstrated under some
transplantation conditions pointing to the possibility that KIR-
HLA interactions are important in tumor control.
Activating KIRs and Haplotypes for
Predicting NK Cell Potency Against Cancer
A study with mixed hematological malignancies reported that in
the context of KIR-HLA ligandmismatch, donor haplotype Bwith
high activating KIR genes (4–8 versus 1–3) was associated with
poor disease-free survival (194), consistent with the disarming
theory (198). However, they also analyzed impact of single KIR
genes on relapse and revealed increased risk for AML, MDS,
and CML patients transplanted with donors possessing KIR3DS1,
KIR2DS1, and KIR2DS5. The latter two also display high link-
age disequilibrium with KIR2DS3. Other studies demonstrated
improved relapse-free and overall survival for AML patients with
haplotype B (199), with the strongest prediction in the cen-
tromeric B region (Cen B) (200). Recently, haplotype B with
telomeric A/B genotype, KIR2DL5, and KIR2DL1 in the presence
of HLA-C2 strongly predicted post induction minimal residual
diseasewith 100% sensitivity and 80% specificity in a cohort of 244
childhood lymphoblastic leukemia (201). We recently reported
that NK cells isolated from healthy donors with haplotype B,
KIR2DS2, and centromeric A/B or B/B, telomeric A/A or A/B
genotype were the most potent against GBM cells in vitro and
in vivo in mice compared to donors with KIR2DS4 (haplotype A,
centromeric A/A, telomeric A/A) and KIR2DS2-/KIR2DS4- neg-
ative donors (centromeric A/A, telomeric A/A, A/B, or B/B) (40).
The KIR2DS2+ NK cell subsets constitutively elevated CD69 and
CD16 activation markers that remained elevated when in contact
with GBM target cells. The KIR2DS2+ NK cell subsets preferen-
tially degranulated granzyme A from elevated LAMP-1+ cytolytic
lysosomes (40). Others reported that KIR2DS1+ NK cells from
HLA-C1 donors efficiently lysed target cells with HLA-C2 ligand
in vitro (202), although this was possibly mediated through KIR-
HLA mismatch. Another study with fewer patients demonstrated
contradicting results of worse outcome (203). The presence of
KIR3DS1 was reported to decrease relapse rates in Bw4+ recip-
ients (204), diminish risk for acute GvHD, and increase overall
survival (205, 206). These effects were potentiated in the presence
of two copies of KIR3DS1 gene. From these cumulative studies,
it appears both inhibitory and activating KIRs are important for
anti-tumor responses, although qualitative differences in the com-
posite KIRs defining the haplotypes may be better predictive of
treatment response.
Ultimately, cytotoxicity requires that the NK cell contacts its
target cell and form a functional immunological synapse (207,
208) for optimal site directed secretion of perforin and granzymes
A/B proteases (Figure 3). Intuitively, treatment response is also
determined by the sensitivity of the cancer cells to the par-
ticular mode of death induced. Granzyme B induces rapid,
intrinsic apoptosis mediated through cleavage of BH3-only pro-
apoptotic protein Bid, cytochrome c, and downstream effector
caspases 3 and 8 (209). Activated NK cells also express Fas Lig-
and [CD95L, (196), TNF-α, and TNF-related apoptosis induc-
ing ligand (TRAIL)], and ligation of Fas (CD95) or TNF-α
to death receptors leads to apoptosis of the receptor-bearing
cell (67) (Figure 3). Although GBMs express the DR4, DR5
TNFR death domains, and CD95, they are inherently resistant to
TRAIL and FasL. This is possibly due to deregulated downstream
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FIGURE 3 | Immunological synapse and NK cell mediated cell death.
Upon synapsing with target cells, NK cells release proteolytic enzymes,
granzyme A and B, as well as perforins that induce necrotic death. The
ligation of Fas Ligand (FasL) to Fas/CD95 receptor together with the binding
of TNF-α to death receptors induce apoptosis of the tumor cell. NK cell
FcγRIII (CD16) recognizes antibody Fc constant domains resulting in cytokine
secretion and NK cell mediated antibody dependent cellular cytotoxicity
(ADCC). The most abundantly secreted cytokines are TNF-α and IFN-γ.
cascades involving BCL-2 and X-linked inhibitor of apoptosis
proteins (XIAP) (147). Granzyme B also induces cytochrome c
release by cleavage and inactivation of the anti-apoptotic BCL-2-
family member Mcl-1 and substrates such as poly (ADP-ribose)
polymerase (PARP), DNA-dependent protein kinase (DNA-PK),
ICAD, and lamin B to generate double DNA-strand breaks. How-
ever, this signaling cascade is deregulated in solid cancers due
to frequent p53 mutations, for example, in GBMs where p53 is
mutated in 40% of cases (210). This results in upregulation of the
pro-survival proteins, BCL-2 and BCL-XL, but downregulation of
Bax, rendering them refractory to apoptosis (147). In contrast,
granzyme A induced non-apoptotic cell death through release of
ROS (211, 212), cleavage of nuclear lamins and histone H1 that
are required for nuclear envelope stabilization and maintenance
of chromatin structure (212, 213) to facilitate activity of DNAses.
We recently demonstrated that potent alloreactive and highly acti-
vated KIR2DS2+ NK cell subsets killed apoptosis resistant GBM
cells by preferentially degranulating granzyme A (40). Multiple
mechanisms of inducing cell death are necessary to ensure the
elimination of apoptosis-resistant cells (Figure 3).
Clinical Trials Exploiting NK Cell Activity
Against Cancer
Autologous NK Cell Transfer
To circumvent the poor tropism into the tumor of high numbers
of patients’ own NK cells, the latter can be expanded to high
yields, activated ex vivo, and re-infused into patients’ circulation
or tumor. This approach has the advantage of decreased risk
for transplant related infections, graft rejection, or GvHD, lack
of requirement for immunosuppression and histocompatibility
matching. However, patients’ own educated NK cells might be
inhibited to efficiently kill the tumor by self-HLA and the hos-
tile immunosuppressiveTME. Autologous lymphokine-activated
killer cells (LAK: polyclonal fractions of NK and T cells) were
activated ex vivo in IL-2 and re-infused into melanoma and
renal cell carcinoma patients, followed by adjuvant high dose IL-
2 (214). The treatment was partially effective, although limited
by low NK cell composition of the LAK product and severe
toxicity due to IL-2 induced capillary leak syndrome. Further-
more, the adoptively transferred cells failed to persist in vivo.
Although follow-up Phase II studies demonstrated that daily
low dose (1.75 106 IU/m2/day) subcutaneous IL-2 was better
tolerated in relapsed non-Hodgkin’s lymphoma and breast can-
cer patients and expanded cytotoxic T cells, no improvement in
patient outcomes was reported. Instead, the IL-2 treatment also
expanded Tregs (217). One trial using recurrent malignant glioma
patients’ own expanded and enriched NK cell fractions placed
them in an Ommaya reservoir (215, 216, 218) in the resection
cavity. The treatment was supplemented with 100 IU/kg IL-2 at
implantation, followed by low dose IFN-β (6 106 IU/week). The
treatment was tolerated and partial radiological responses were
reported (215). Attempts to circumvent the underlying tolerance
administered a humanized IgG4 antibody IPH2101 that blocks
KIR2DL1, KIR2DL2, and KIR2DL3 inhibitory signaling. How-
ever, as IPH2101 also binds KIR2DS1 and KIR2DS2, it may block
crucial dominant activation signals provided by potent KIR2DS1,
KIR2DS2 NK cell subsets (40). Indeed, IPH2101 has been inves-
tigated in early phase clinical trials for multiple myeloma and
AML, and although few adverse events and toxicity were reported
in multiple myeloma, long lasting objective responses were also
not registered in the patients (219, 220), except for transient
NK cell activation and cytotoxicity ex vivo. The next gener-
ation hinge-stabilized IPH2102 was recently shown to syner-
gize with Lenalidomide to increase NK cytotoxicity of myeloma
patients with FcγRIII and FcγRII polymorphisms treated with
Daratumumab against CD38 (221). While IPH2102 blocked KIR-
inhibitory signaling on the NK cells, Lenalidomide activated them
to increase production of TNF-α, IFN-γ, and granzyme B. The
tumor can also be sensitized to autologous NK cells by coadmin-
istering proteosome inhibitors (e.g., Bortezomib), doxorubicin, or
histone deacetylase inhibitors that upregulate stress ligands for
NKG2D receptors, induce pro-inflammatory cytokines or death
receptors that bind TNF-α. Although Bortezomib was effective
in preclinical models mediated by upregulated death receptors
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(TRAILR1-DR4, TNFR1, DR3 and DR6) as well as stress lig-
ands on the tumor cells, it was not effective in AML and RCC
patients (99, 222). The efficacy of Bortezomibmight be contingent
upon the inherent susceptibility of the tumor cell to undergo
TRAIL and FASL dependent apoptosis. The dose, duration, and
sequence of administration of agents when combining with NK
cells requires fine-tuning as unexpected effects on NK cell func-
tion and or tumor sensitization may occur (223). During NK
cell therapy, concurrent treatment with azacytidine and sorafenib,
which impair PI3K and ERK phosphotylation might also ham-
per NK cell activity and be counter productive in augmenting
tumor cell kill by the immunological mechanisms (224, 225).
Lenalidomide was shown to enhance Rituximab induced ADCC
against non-Hodgkin lymphoma and B-cell chronic lymphocytic
leukemia through enhanced CD4+ T cell dependent IL-2 release,
resulting in augmented NK cell activation, granzyme B, and FasL
release (226). NK cells could also be stimulated to enhanced acti-
vation, proliferation, and persistence with anti-CD137 agonistic
antibodies.
Allogeneic NK Cell Transfer
Due to challenges posed by tolerance to self-cells, infusions of allo-
geneic NK cells derived from related or HLA-matched unrelated
donors are increasingly pursued for adoptive cellular therapies.
The cells can be obtained from donor bone marrow progeni-
tors, umbilical cord, or peripheral blood leukapheresis product.
Subsequently, T lymphocytes and B cells are depleted with anti-
CD3 or anti-CD19 microbeads, respectively. This is essential to
prevent GvHD and lymphoproliferative disorders (227) induced
by transfer of T cells and Epstein Barr virus (EBV) transformed
B cells, respectively. To prevent GvHD, the final T cell dose
should be<3 105 cells/kg or below 0.1% total lymphocyte count
(99, 228). 1 108 purified allogeneic NK cells have been safely
transfused to patients withoutmajor toxicity, although a threshold
of maximum tolerated doses have yet to be established. Initial
studies demonstrated that absence of recipient lymphoid and
myeloid cell depletion prior to donor cell infusion resulted in
diminished NK cell persistence in vivo and reduced therapeu-
tic efficacy. Thus, an immune suppressive “preparative” regi-
men became imperative prior to donor cell infusions. In a non-
transplant treatment of AML patients, investigators compared low
dose non-myeloablative fludarabine (25mg/m2/day) for 5 days
or high cyclophosphomide (60mg/m2/day) for 2 days chased by
fludarabine (25mg/m2/day) for 5 days (Hi-Cy/Flu) prior to donor
NK cell infusions and adjuvant IL-2 (1.75 million U/m2) for
14 days. Only patients receiving Hi-Cy/Flu regimen had in vivo
detectable NK cells in peripheral blood 2weeks post treatment
based on PCR donor-recipient chimerism assay and measurable
circulating IL-15 levels (99). Thus, depletion of the lymphoid
and myeloid cells that also utilize and compete for IL-15 resulted
in elevated serum levels of IL-15 and IL-7, allowing for home-
ostatic proliferation and expansion of the NK and CD8T cells
in vivo. Objective therapeutic responses were correlated with
the prolonged presence of donor NK cells in the recipient. The
infused NK cells were tolerated and did not induce GvHD and
notably, 25% high risk, poor prognosis AML patients exhibited
complete responses (229). This regimen is widely used withminor
modifications for trials in leukemia, non-Hodgkin’s lymphoma,
breast, ovarian, and NSCLCs. Allogeneic NK cells combined with
2weeks’ adjuvant IL-2 were administered in a phase II trial in 20
patients with solid tumors (14 ovarian, 6 breast cancer) following
the low dose, non-myeloablative preparative regimen (230). Very
few peripheral blood NK cells were detected after 1 week in the
majority of patients and the expanded cells were mostly Tregs
(99) due to the IL-2 treatment. Although proven safe in these
settings, a major bottleneck to clinical efficacy remains consistent
in vivo NK cell expansion and abrogation of the tumor induced
immunosuppressive mechanisms.
Methods for Expanding NK Cells in High
Numbers
Cytokines
Depending on whether a lymphodepletive regimen is given, typi-
calNK cell infusionsmay vary from8–20 106 to 1 109 cells/kg.
In unconditioned patients, high NK cells doses are required to
achieve therapeutic effects, thus high throughput expansion
methods are required. Moreover, since NK cells constitute only
10–15% of peripheral blood lymphocytes, and freshly isolated
cells are in resting state and not optimally cytotoxic, activation
by cytokines in culture is additionally required. Initially,
cytokine cocktails were administered in vivo but they evoked
disappointing efficacy in clinical studies largely due to toxicity, or
activation-induced cell death (AICD), or exhaustion (231) where
the effector cells succumbed to apoptosis upon contact with
vascular endothelium. Recently, cytokine therapy in preclinical
studies demonstrated that IL-12, IL-18, and the genetically
engineered “superkine” H9 reverted the functional anergy of
NK cells that was induced by class I MHC deficient tumors and
prolonged animal survival (232). NK cell stimulation with IL-12
and IL-18 elevated expression of T-cell immunoglobulin and
mucin domain-containing (Tim)-3 receptor (233), previously
associated with T cell exhaustion (234). However, in this study,
TIM-3 was conversely proposed to denote NK cell activation
and maturation, and only weakly suppressed NK cell cytotoxicity
(233). “Memory” NK cells with enhanced proliferation and IFN-γ
production could be generated by pre-activation with a cytokine
cocktail including IL-12, IL-18, and IL-15 followed by a 3-week
recovery period prior to re-stimulation with IL-12+ IL-15, or
IL-12+ IL-18, or K562 (235). IL-2 increases NK cytotoxicity
in vitro by increasing density of activation receptors (236), and
sustains NK survival in vivo but off-target effects associated
with vascular leak syndrome induced by stimulation of IL-2R
on endothelial cells are problematic. The H9 superkine that
signals independently of the IL-2Rα chain (237) may redress the
above shortcoming and derive therapeutic benefits in the clinic.
Combination IL-2 and IL-15 markedly prolongs NK cell survival.
Uniquely, IL-15 inhibits IL-2 dependent AICD, (238) and
decreases expression of PD-1. IL-15 promotes NK cell survival
and expansion, especially when presented to NK cells in trans as a
membrane bound complex with IL-15Rα by DCs andmonocytes.
Recently, a first in human trial investigated safety and maximum
tolerated dose of a recombinant human (rh) IL-15 in patients
with metastatic malignancy (239). Higher doses of IL-15 resulted
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in rapid redistribution of NK and CD8T cells from peripheral
blood within 48 h followed by hyper-proliferation, where NK cells
expanded upto 10-fold of baseline. The cells were highly activated
and intensely released cytokines, IL-8, IL-10, TNF-α, IL-1β, IL-6,
and IFN-γ , resulting in radiologically visible anti-tumor effects
in some patients. However, the treatment was associated with
dose limiting severe adverse events and the authors concluded the
MTD for IL-15 in this format was 0.3mg/kg/day (239). In other
studies, CD34+ progenitor cells from umbilical cord blood (UCB)
cells could be differentiated to NK cells in medium supplemented
with low-dose GM-CSF, G-CSF, IL-6, and a high-dose cytokine
cocktail consisting of IL-7, stem cell factor (SCF), IL-15, and IL-2.
However, the cells displayed low CD16 and KIR expression at
the end of the culture process (240, 241). Alternatively, CD34+
cells from adult peripheral blood could be differentiated in the
presence of SCF, FLT3 ligand, IL-7, and hydrocortisone, followed
by IL-7, IL-15, and hydrocortisone. No major toxicity was
recorded when using these cells (240). These methods typically
produce small-scale NK expansions in the range 10- to 20-fold
that might not be sufficient to treat patients in trials.
Feeder Cells
Coculture of CD56+ purified NK cells with irradiated feeder cells
has been demonstrated to expand and activate NK cells from T
and B cell depleted peripheral blood of patients 800- to 1000-fold
in a short time scale of 2weeks (236). This NK cell product upreg-
ulated expression of NKG2D, NKG2C, secreted FasL, IFN-γ, IL-2,
TRAIL, Granzymes A/B, and was highly cytotoxic against targets.
The EBV transformed lymohoblastoid (EBV-LCL) feeder cells
were irradiated with 100Gy and cocultured in 500 IU/ml IL-2 at
20:1 ratiowith 2 108 purified peripheral bloodNKcells obtained
from 15 l leukapheresis product. Clinical grade NK cells expanded
upto 3 1010 within a 3-week period (236). However, attempts
to further expand beyond this failed, and it is not clear if this is
due to AICD or replicative senescence due to shortened telom-
eres. Importantly, this study also demonstrated that previously
expanded and frozenNKcells, when subsequently thawed, require
further activation in culture with IL-2 to maintain their cytotoxi-
city although their viability is substantially compromised. Others
have utilized feeder cell-free, automated bioreactor systems to
expand highly cytotoxic cells frompolyclonal PBMCswith 77-fold
yield in 21 days. However, these were impure and consistedmostly
T cells (CD3+CD56-) and NKT cells (CD56+CD3+) (242). This
product had very low NK cells, average 38% (range 10–80%), and
bears the treatment limiting risk of inducing GvHD. However,
an autologous setting may be more permissive of T cell con-
tamination, although they may differentiate into Tregs. Further
manipulation to deplete the T cells prior to infusion in the patient
would be required and is potentially costly (243). The K562 CML
cells have been engineered to express membrane bound IL-15
gene fused to CD8α transmembrane domain as well as membrane
bound 4-1BBL (mb15-41BBL) and shown to induce nearly 22-fold
NK expansion within 1week culture in 10 IU/ml IL-2 (244). In
other studies, K562-based artificial antigen presenting cells were
modified to express membrane bound IL-15 or IL-21 (245). Upon
comparison, MbIL-21 expanded cells were superior to mbIL-15
expanded NK cells in that they exhibited an activated phenotype
(denoted by elevated CD160 expression, (246), proliferated better,
and elongated their telomeres (postulated due to STAT3 depen-
dent signaling). They retained expression of KIR, CD16, produced
cytokines, and were potent mediators of cellular cytotoxicity.
Depending on the class I HLA ligands expressed on the surface
of the feeder cells, it may be possible to selectively expand NK
cells with particular KIR repertoires selected for potent efficacy
(247). Since the alloreactive fraction in the polyclonal NK cell
pool varies widely from 0 to 62% among potential donors (177),
not all individuals are expected to be potent donors. Improv-
ing our understanding of molecular KIR/HLA combinations that
predict best therapeutic benefit is imperative in next generation
NK cell therapy. We recently demonstrated that donor NK cells
with KIR2DS2 immunogenotype exhibited potent efficacy against
GBM targets (40), even though they represented only 36% of the
total NK cell pool. It is highly compelling to investigate whether
selective expansion of these highly activated KIR2DS2 NK cell
fractions would yield greater clinical benefits for GBM patients
than using bulk NK cells.
Conclusion and Perspectives
Our deeper understanding of NK cell biology and function in
anti-cancer immunity, the increasingly precise methodologies for
their characterization, purification, and expansion have all height-
ened our interest in exploring the applicability of NK cells for
cancer immunotherapy. However, good manufacturing practice
approved protocols for generating high quantities of pure, acti-
vated NK cells for repeated infusion into patients remain com-
plicated, expensive, and are still somewhat experimental. Like-
wise, appropriate conditioning regimens to prevent graft rejection,
that can be used for a wide range of cancer types, the right
choice of exogenous cytokines to safely sustain homeostatic NK
cell expansion, activation, and survival in vivo are all issues still
under investigation. Nevertheless, concerted research efforts are
underway to refine and renew the protocols to establish NK
cells as efficacious effectors against malignancy. It is intriguing
that the multitude of ways to enhance NK cytotoxicity seems
to impact fundamental regulatory mechanisms such as receptor-
ligand mismatch, expression of activating receptors, increasing
receptor affinity, augmentation of ADCC. All the same, we do
not yet know how to reap maximal benefit of this expertise in
the clinic. It may be because the clearest evidence accrued so
far is most often seen in larger cohort studies. Nevertheless, the
salient question is what will it take to make NK cell therapy
standard care for GBM and other solid cancers? Due to the poor
tumor infiltration and limited passage across the blood brain
barrier (39, 248), NK cell therapy in the brain might be best
suited as a haplotype-matched, intralesional combination NK cell
therapywithmAbs. ExploitingNKcell subsetswith best predictive
KIR/HLA combinations might be advantageous, since autologous
NK cells previously demonstrated limited efficacy. For this to be
effective, tumor reduction prior to NK therapy is an imperative in
order to give the NK cells a task they can manage. The cells could
be injected into and around the resection cavity and administered
as an adjuvant therapy post standard treatment that combines
debulking surgery, concomitant Temozolomide chemotherapy,
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and conformal ionizing radiation (249). This would exploit the
period of a relative immune compromise (250) to promote
homeostatic proliferation of grafted cells and prevent graft rejec-
tion. A phase I dose escalation toxicity study would be required
as the brain may present unique toxicity and necessitates care-
ful trial design. Strategies to consider might be single treatment
with high numbers (effector: target ratios) of maximally activated
cells or lower numbers and repeated doses to promote in vivo
persistence in the recipient. We recently demonstrated in pre-
clinical models that large, single NK cell doses were efficient
and tolerated whereas repeated high doses were poorly toler-
ated in mice (40). If these results were translatable to humans,
in a patient phase I trial, smaller dose escalations with maxi-
mally alloreactive subsets may be better tolerated, not least more
feasible with regards to ex vivo NK cell expansions. Moreover,
we demonstrated using multiparametric physiological magnetic
resonance imaging (MRI) to identify predictive biomarkers, that
2 106 intralesional NK cells were more effective compared to
1 106 cells, even when these were combined with mAb9.2.27 in
nude rats (158, 251). Ultimately, NK cells in solid tumors should
be combined with mAbs against abundant tumor specific anti-
gens to enhance their efficacy via ADCC and overcome inherent
immunosuppression in the tumor bed (158). Immunologic surro-
gates that predict efficacy in patients could be IFN-γ , as this has
been previously correlated with anti-tumor responses and overall
survival (103).
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